Renal anemia and L-carnitine therapy in hemodialysis patients

Hadi Tabibi


DOI10.4172/2472-1921.100004
Hadi Tabibi*

Department of Clinical Nutrition & Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran.

*Corresponding Author:
Dr. Hadi Tabibi
Associate Professor (PhD), Department of Clinical Nutrition & Dietetics
Faculty of Nutrition and Food Technology
National Nutrition and Food Technology Research Institute
Shahid Beheshti University of Medical Sciences, Tehran
198396-3113, Islamic Republic of Iran
Tel: 00989122445367
E-mail: hadtabibi@yahoo.com

Received date: Ocotber 25, 2015; Accepted date: Ocotber 28, 2015; Published date: November 04, 2015

Citation: Tabibi H. Renal anemia and L-carnitine therapy in hemodialysis patients. J Clin Nutr Diet. 2016, 1:4. doi: 10.4172/2472-1921.100004

Visit for more related articles at Journal of Clinical Nutrition & Dietetics

Renal anemia is a common complication in hemodialysis (HD) patients, and resulting mainly from reduced erythropoietin production [1,2]. Renal anemia can result in reduced exercise tolerance, impaired cognition, depression, dyspnea, heart failure and increased mortality in HD patients [1,2]. Erythropoietin therapy is a standard treatment for renal anemia; however, 5–10% of HD patients show erythropoietin resistance [1,3].

The most common cause of erythropoietin resistance is reduced iron availability, including absolute and functional iron deficiency [2]. Hepcidin, a 25-amino-acid peptide predominantly produced by liver, decreases the release of iron from storage tissues and causes a reduction in iron absorption from the gut (3). Therefore, hepcidin is involved in the pathogenesis of erythropoietin resistance [3]. Inflammation increases hepcidin production, limiting the availability of iron for erythropoiesis and thus providing a direct link between inflammation and erythropoietin resistance [1]. The reduction of inflammation is a reasonable approach for treating erythropoietin resistance.

Carnitine deficiency, like anemia and inflammation, is prevalent in HD patients and causes by low dietary intake, impaired de novo carnitine renal synthesis, and loss of free carnitine from body during hemodialysis [4]. It has been shown that dialysis patients with anemia have lower serum carnitine than nonanemic renal patients and need higher doses of erythropoietin [5]. To date, all studies (i.e. 8 trials) on the effects of L-carnitine supplement on inflammation, except one, showed that L-carnitine could significantly reduce serum inflammation markers in HD patients [6]. In addition, according to available literature, the majority of trials indicated that L-carnitine administration might have a beneficial effect on renal anemia management in dialysis patients. Eight trials showed that L-carnitine supplement in dialysis patients increased hemoglobin concentration [7-12] and decreased erythropoietin requirement [5,9,10] or erythropoietin resistance index [13]. However, some studies reported that L-carnitine supplement had no effect on hemoglobin concentration or erythropoietin requirement [14-17]. Therefore, L-carnitine supplement can be used as an adjuvant therapy to improve erythropoietin efficiency for the treatment of renal anemia in dialysis patients, especially those with carnitine deficiency or erythropoietin resistance.

References

open access journals, open access scientific research publisher, open access publisher
Select your language of interest to view the total content in your interested language

Viewing options

Flyer image

Share This Article